Ardelyx Q2 2024 Earnings Report $5.78 -0.58 (-9.14%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Ardelyx EPS ResultsActual EPS-$0.07Consensus EPS -$0.11Beat/MissBeat by +$0.04One Year Ago EPS-$0.08Ardelyx Revenue ResultsActual Revenue$73.20 millionExpected Revenue$55.03 millionBeat/MissBeat by +$18.17 millionYoY Revenue Growth+228.30%Ardelyx Announcement DetailsQuarterQ2 2024Date8/1/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseARDX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Ardelyx Earnings HeadlinesArdelyx Tops Estimates as Sales SurgeFebruary 20 at 1:58 PM | fool.comArdelyx reports Q4 EPS 2c, consensus 0cFebruary 20 at 9:15 AM | markets.businessinsider.comThis Crypto Is Set to Explode in FebruaryTrump’s World Liberty Bought $1M of THIS Coin Early investors could reap HUGE benefits…February 20, 2025 | Crypto 101 Media (Ad)Ardelyx reports Q4 EPS 2c, consensus 0cFebruary 20 at 9:15 AM | markets.businessinsider.comArdelyx, Inc. Reports Strong Financial Results for 2024 with $333.6 Million in Revenue and Reaffirms Peak Sales Projections for IBSRELA and XPHOZAHFebruary 20 at 8:00 AM | quiverquant.comArdelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateFebruary 20 at 7:30 AM | globenewswire.comSee More Ardelyx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ardelyx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ardelyx and other key companies, straight to your email. Email Address About ArdelyxArdelyx (NASDAQ:ARDX), a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.View Ardelyx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Home Depot (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
